公开(公告)号：US20230201283A1

公开(公告)日：2023-06-29

申请号：US17790160

申请日：2021-01-05

Applicant: Pfizer Inc.

Inventor： Joseph John Binder ,  Michael Dale Eisenbraun ,  Douglas Hanahan ,  David H. Kirn ,  Clare Lees ,  Prajit Limsirichai ,  Liliana Maruri Avidal

IPC: A61K35/768 ,  C12N15/86 ,  A61K39/395 ,  C07K14/55 ,  C12N9/12 ,  A61P35/00

CPC classification number: A61K35/768 ,  A61K39/3955 ,  A61P35/00 ,  C07K14/55 ,  C12N9/1211 ,  C12N15/86 ,  C12Y207/01021 ,  C12N2710/24132 ,  C12N2710/24143

Abstract: The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus (RVV), compositions comprising the RVV, and use of the RVV or composition for inducing oncolysis in an individual having a tumor.

公开(公告)号：US20220033784A1

公开(公告)日：2022-02-03

申请号：US17371206

申请日：2021-07-09

Applicant: Pfizer Inc.

Inventor： Joseph John Binder ,  Michael Dale Eisenbraun ,  Clare Lees ,  Jeremy Shawn Myers ,  James Travis Patterson

IPC: C12N7/00 ,  C07K14/55 ,  A61K35/768 ,  A61P35/00

Abstract: The present disclosure provides human IL-2 variants, recombinant oncolytic viruses comprising the IL-2 variant, compositions comprising the IL-2 variant or recombinant oncolytic virus, and use of the IL-2 variants, recombinant oncolytic virus, or compositions for treating cancer in an individual.